2021-01-07,X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference
2021-01-04,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-12-18,X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher
2020-12-14,"X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer"
2020-12-10,X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome
2020-12-07,Is XFOR A Good Stock To Buy Now?
2020-12-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-10,X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
2020-11-05,X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results  and Provides Corporate Update
2020-11-02,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-02,"X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer"
2020-10-31,"Kaskela Law LLC Announces Stockholder Investigation of X4 Pharmaceuticals, Inc. - XFOR"
2020-10-22,"X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020"
2020-10-08,X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome
2020-10-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-01,X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton
2020-09-03,X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences
2020-09-02,X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in Blood - the Official Journal of the American Society of Hematology
2020-09-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-08-10,X4 Pharmaceuticals to Present and Participate in the Canaccord Genuitys 40th Annual Growth Conference
2020-08-05,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-30,X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results  and Provides Corporate Update
2020-07-16,"X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020"
2020-07-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-26,"Do Hedge Funds Love X4 Pharmaceuticals, Inc. (XFOR)?"
2020-06-12,X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020
2020-06-11,"X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer"
2020-06-08,X4 Pharmaceuticals to Host Conference Call and Webcast to Discuss New Phase 2 Clinical Data for Mavorixafor in WHIM Syndrome to be Presented at 25 European Hematology Association Annual Congress
2020-06-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-28,X4 Pharmaceuticals to Present at Two June Virtual Investor Conferences
2020-05-14,X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract
2020-05-13,Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade
2020-05-12,X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
2020-05-07,"X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results"
2020-04-23,"X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020"
2020-04-09,X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference
2020-04-07,X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar
2020-04-01,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-03-25,X4 Pharmaceuticals to Host 2020 Analyst Day Webinar:A Deep Dive into WHIM Syndrome
2020-03-20,Maryland biotech CEO: Virus outbreak won't stop opening of Boston R&D hub
2020-03-12,X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-02,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-02-27,"X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020"
2020-02-25,X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
2020-02-12,X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor
2019-12-30,X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenströms Macroglobulinemia (WM)
2019-12-26,Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks
2019-12-23,"Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR"
2019-12-20,"Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)"
2019-12-16,X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
2019-12-03,X4 Pharmaceuticals Enters Oversold Territory
2019-11-26,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-26,X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
2019-11-26,X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
2019-11-26,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug"
2019-11-25,X4 Pharmaceuticals Announces Proposed Public Offering
2019-11-15,X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference
2019-11-12,X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome
2019-11-07,X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
2019-11-07,"X4 Pharmaceuticals, Inc. to Host Earnings Call"
2019-11-05,X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
2019-11-04,"X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel"
2019-10-25,"X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019"
2019-09-30,X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients
2019-09-27,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-23,X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
2019-09-18,"X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development"
2019-09-17,X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences
2019-09-12,X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress
2019-08-29,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-08-06,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-07-30,X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome
2019-07-24,X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences
2019-06-26,X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
2019-06-12,X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
2019-05-15,X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenströms Macroglobulinemia
2019-04-24,"X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer"
2019-04-12,X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
2019-04-11,X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
2019-04-02,"X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors"
2019-04-01,X4 Pharmaceuticals Provides Business and Clinical Development Update
